Drug Type Monoclonal antibody |
Synonyms ATLX 1088, ATLX1088 |
Target |
Mechanism CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Alchemab Therapeutics Ltd.Startup |
Active Organization Alchemab Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | GB | Alchemab Therapeutics Ltd.Startup | 22 Jun 2023 |